Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Cassier

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Cell Reports. Medicine|October 8, 2025
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1Jean-Luc Van Laethem, Karen Geboes, Ivan Borbath, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2020
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCRSouad Assaad, Virginie Avrillon, Marie-Line Fournier, et al.
Science (New York, N.Y.)|January 19, 2023
Heritable defects in telomere and mitotic function selectively predispose to sarcomasMandy L Ballinger, Swetansu Pattnaik, Piyushkumar A Mundra, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Cell Reports. Medicine|October 8, 2025
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1Jean-Luc Van Laethem, Karen Geboes, Ivan Borbath, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2020
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCRSouad Assaad, Virginie Avrillon, Marie-Line Fournier, et al.
Science (New York, N.Y.)|January 19, 2023
Heritable defects in telomere and mitotic function selectively predispose to sarcomasMandy L Ballinger, Swetansu Pattnaik, Piyushkumar A Mundra, et al.
Pageof 6